What Edgewise Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 1 |
| Sells | 3 | 17 |
| Total trades | 6 | 35 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 40,152 | 567,454 |
| Disposed | 17,971 | 555,030 |
| Net activity | +22,181 | +12,424 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Fox Jonathan C | Director | Oct 01 | Grant / award · A | +308 | — | — | 25,141 |
| Koch Kevin | President and CEO | Aug 12 | Sale for tax withholding · S | −913 | $44.33 | −$40.5K | 52,488 |
| Koch Kevin | President and CEO | Aug 12 | Sale for tax withholding · S | −8,276 | $43.66 | −$361K | 53,401 |
| Koch Kevin | President and CEO | Aug 12 | Sale for tax withholding · S | −8,782 | $43.64 | −$383K | 61,677 |
| Koch Kevin | President and CEO | Aug 12 | Exercise / conversion · M | +21,875 | — | — | 70,459 |
| Koch Kevin | President and CEO | Aug 12 | Exercise / conversion · M | +17,969 | — | — | 48,584 |
| Fox Jonathan C | Director | Jul 01 | Grant / award · A | +319 | — | — | 24,833 |
| Russell Alan J | Chief Scientific Officer | Jul 01 | Open-market sale · S | −69,648 | $39.41 | −$2.74M | 24,555 |
| Russell Alan J | Chief Scientific Officer | Jul 01 | Open-market sale · S | −130,352 | $39.41 | −$5.14M | 94,203 |
| Russell Alan J | Chief Scientific Officer | Jul 01 | Exercise / conversion · M | +69,648 | $0.18 | +$12.5K | 224,555 |
| Russell Alan J | Chief Scientific Officer | Jul 01 | Exercise / conversion · M | +130,352 | $0.45 | +$58.7K | 154,907 |
| Donovan Joanne M. | CMO | May 05 | Disclosed 10b5-1 sale · S | −50,000 | $38.57 | −$1.93M | 4,367 |
| Donovan Joanne M. | CMO | May 05 | Exercise / conversion · M | +50,000 | $7.08 | +$354K | 54,367 |
| Donovan Joanne M. | CMO | May 04 | Disclosed 10b5-1 sale · S | −5,230 | $31.29 | −$164K | 4,367 |
| Donovan Joanne M. | CMO | Apr 01 | Disclosed 10b5-1 sale · S | −28,662 | $32.31 | −$926K | 9,597 |
| Donovan Joanne M. | CMO | Apr 01 | Exercise / conversion · M | +28,662 | $7.08 | +$203K | 38,259 |
| Fox Jonathan C | Director | Apr 01 | Grant / award · A | +339 | — | — | 24,514 |
| Donovan Joanne M. | CMO | Mar 31 | Disclosed 10b5-1 sale · S | −21,338 | $32.12 | −$685K | 9,597 |
| Donovan Joanne M. | CMO | Mar 31 | Exercise / conversion · M | +21,338 | $7.08 | +$151K | 30,935 |
| Donovan Joanne M. | CMO | Mar 27 | Open-market sale · S | −6,735 | $30.98 | −$209K | 9,597 |
Loading...
